Ultragenyx stock holds Buy rating, $140 target from Truist
Truist Securities maintained a positive outlook on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), reiterating a Buy rating and a price target of $140. The firm's analyst highlighted the company's ...
Is Truist Financial Corporation (TFC) the Best Bank Dividend Stock to Buy Right Now?
We recently compiled a list of the 10 Best Bank Dividend Stocks To Buy Right Now. In this article, we are going to take a ...
Truist Financial Sticks to Its Hold Rating for Alpine Income Property Trust Inc (PINE)
Truist Financial analyst Anthony Hau maintained a Hold rating on Alpine Income Property Trust Inc (PINE – Research Report) on February 11 and ...
Truist Financial Keeps Their Buy Rating on Plains GP Holdings (PAGP)
Truist Financial analyst Neal Dingmann maintained a Buy rating on Plains GP Holdings (PAGP – Research Report) on February 11 and set a price ...
10 Best Bank Dividend Stocks To Buy Right Now
For this list, we picked the top 10 bank dividend stocks based on their popularity among elite hedge funds in the third ...
2025 Results Will Be Key for Truist's Progress on New Return Target; Fair Value Estimate Unchanged
We are maintaining our fair value estimate for Truist Financial at $47 per share. We value the firm at roughly 1.6 times tangible book value as of the end of 2024.
Business leaders could play key role in Charlotte's $25B transit push
Charlotte Area Transit System interim CEO Brent Cagle said today that support from the local business community will be ...
Truist maintains Buy on Genmab stock, price target at $50
Truist Securities reiterated their Buy rating on Genmab A/S (NASDAQ:GMAB) with a steady price target of $50.00. The firm's analysts remain confident in the biotech company's prospects, particularly in ...